Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morning versus evening administration of amlodipine + valsartan for blood pressure control
IRCT20240131060872N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amlodipine and valsartan in hypertension (HTN) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Blood pressure control after 8 weeks and Drug side effects. Started Apr 2024; status: completed.
02
Drugs
amlodipinevalsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on IRCT20240131060872N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240131060872N1.